Breaking News

Lloyds Reaches $370 Million Settlement With Regulators Over Libor
Tweet TWEET

Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report

Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way
     for Solid Footing in Healthcare - Research Report on Pfizer, Merck,
            Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 17, 2013

NEW YORK, June 17, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company
(NYSE: BMY), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Pfizer Inc. Research Report

On June 12, 2013, Pfizer Inc. (Pfizer) announced that it has reached a $2.15
billion settlement with Teva Pharmaceuticals and Sun Pharmaceuticals for
patent-infringement damages related to the launches of the generic Protonix in
the US. Amy W. Schulman, Executive Vice President and General Counsel of
Pfizer, said, "We are pleased with today's settlement, which recognizes the
validity and value of the innovation that led to Protonix." Schulman added,
"Protecting intellectual property is vital as we develop new medicines that
save and enhance patients' lives." Pfizer will receive 64% of the
compensation, and the remaining will be given to Nycomed, which is now part of
Takeda. The Full Research Report on Pfizer Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/db02_PFE]

--

Merck & Co. Inc. Research Report

On June 12, 2013, Merck & Co. Inc. (Merck) commented on the NIDDK-NCI Workshop
and the American Diabetes Association's (ADA) call for an independent review
of data about the safety of incretin-based diabetes medicines, including GLP-1
analogs and DPP-4 inhibitors, such as Januvia (sitagliptin). Michael
Rosenblatt, M.D., Chief Medical Officer of Merck, stated, "Nothing is more
important to Merck than the safety of our medicines and the people who take
them. We welcome opportunities to discuss the data that support the safety
profile of sitagliptin in the treatment of adults with type 2 diabetes. Type 2
diabetes is a disease with serious consequences if left untreated." Rosenblatt
continued, "We are committed to participating in an independent review of our
data, and will join the ADA in planning for such an initiative." The Full
Research Report on Merck & Co. Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WSReports.com/r/full_research_report/400f_MRK]

--

Bristol-Myers Squibb Company Research Report

On June 12, 2013, Bristol-Myers Squibb Company (Bristol Myers Squibb) and
AstraZeneca announced that they will continue to work with health authorities
and scientific experts around the world to closely monitor the use of our
GLP-1 receptor agonist and DPP-4 inhibitor through comprehensive surveillance
programs to ensure patients and physicians have a clear understanding of the
risk/benefit profile of these medications. This announcement came after the
American Diabetes Association (ADA) called for incretin-based therapies
manufacturers to make available the patient-level data from clinical trials
for an independent analysis of pancreatic safety. The Full Research Report on
Bristol-Myers Squibb Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/88a2_BMY]

--

Keryx Biopharmaceuticals Inc. Research Report

On June 3, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) announced the
presentation of updated efficacy and safety data from the Phase 3 long-term
clinical trial of ZenerexZerenex (ferric citrate). Based on the efficacy
results, Keryx determined that Zerenex is an efficacious and safe oral
phosphate binder that controls serum phosphorus, increases iron stores as
measured by serum ferritin and TSAT, and reduced the use of IV iron and ESAs,
while sustaining hemoglobin as compared to the active control group.
ZenerexZerenex met the pre-defined primary and key secondary endpoints for the
treatment of elevated serum phosphorus levels, or hyperphosphatemia, in
patients with end-stage renal disease (ESRD) on dialysis. The Full Research
Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WSReports.com/r/full_research_report/27d7_KERX]

--

Pacira Pharmaceuticals,Inc. Research Report

On May 29, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced the findings
from the completed first part of its Phase 2/3 clinical trial for the
assessment of the use and administration of Exparel (bupivacaine liposome
injectable suspension) as a single-dose injection femoral nerve block for
total knee arthroplasty surgery (TKA). Dave Stack, President and CEO of
Pacira, stated, "We are pleased with the interim analysis of the safety and
efficacy of EXPAREL in this important orthopedic indication." Stack continued,
"Based on the independent Data Safety Monitoring Board analysis, we believe
that a single-dose injection of EXPAREL as a femoral nerve block can provide
several days of analgesia without significant motor blockade. We look forward
to initiating the Phase 3 portion of this trial and ultimately to providing
orthopedic patients with a new option that could significantly contribute to
the management of their postsurgical pain by replacing a perineural catheter,
drug reservoir and pump with a single-dose injection of EXPAREL." The Full
Research Report on Pacira Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/c8a5_PCRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: +1-310-496-8071